EDITORIAL DESK / CONTACT
Send a Source, Flag a Boundary
Correspondence is for citation corrections, newly reported studies, and precise challenges to how evidence has been characterized.
Editorial correspondence
The editorial desk welcomes evidence-focused notes about semaglutide, tirzepatide, tesamorelin, and retatrutide. Useful messages identify the page, quote the passage at issue, and provide the peer-reviewed article, regulatory record, or clinical-trial publication that supports a correction. Reports of broken reference links, updated trial results, changed approval status, and wording that overstates a design are especially valuable.
Editorial mailbox: editors@medical-peptides.com
Submissions are reviewed for relevance and source quality. A message may lead to a correction, a clarification, or a note that the proposed source does not support the requested claim. Publication and reply are not guaranteed. Commercial pitches, placement requests, sponsored-content proposals, and supplier listings are outside the scope of this desk.
Clinical and sourcing requests
The mailbox cannot answer questions about personal treatment, eligibility, side effects in a specific case, dosing, reconstitution, switching medicines, or combining therapies. It also cannot locate a prescriber, pharmacy, vendor, clinical-trial placement, or research-labeled material. Retatrutide remains investigational in the evidence reviewed here, and a commercial listing does not provide the oversight of a registered trial.
Urgent health concerns require an appropriate local medical service. Non-urgent personal questions belong in a licensed clinician-patient relationship, where medical history, current medicines, examination, and jurisdiction-specific labeling can be considered. This boundary protects the function of the site: a literature review can explain what a study design found, but it cannot convert population evidence into an individual decision. General educational questions may inform future coverage, but they will be reframed around published evidence rather than answered as case-specific guidance. Messages are retained only as editorial working material for this independent review desk.